Acumen Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 23.13K shares.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 91.83K shares, a 181.80% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 1.94K shares.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 34.53K shares.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 111.21K shares, a 15.51% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 131.63K shares, a 2439.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 23.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 116.91K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 91.83K shares 10-Q · filed 2026-05-12 | 93.77K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 1.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 34.53K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2025-03-31 | 32.59K shares 10-Q · filed 2025-05-13 | |
| 2024-12-31 | 0.00 shares 10-K · filed 2026-03-26 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 111.21K shares 10-K · filed 2024-03-26 |
| 2022-12-31 | 99.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 131.63K shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 1.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-12-31 | 2.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 5.18K shares 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |